CoChat

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent

Open access
Pantziarka, Pan, Sukhatme, Vidula, Bouche, Gauthier, Melhuis, Lydie, Sukhatme, Vikas P · 2016 · ecancermedicalscience
Cited by 118

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug (NSAID), with a range of actions which are of interest in an oncological context. While there has long been an interest in the use of NSAIDs in chemoprevention, there is now emerging evidence that such drugs may have activity in a treatment setting. DCF, which is a potent inhibitor of COX-2 and prostaglandin E2 synthesis, displays a range of effects on the immune system, the angiogenic cascade, chemo- and radio-sensitivity and tumour metabolism. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. Based on this evidence the case is made for further clinical investigation of the anticancer effects of DCF, particularly in combination with other agents - with a range of possible multi-drug and multi-modality combinations outlined in the supplementary materials accompanying the main paper.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3332/ecancer.2016.610

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 118

Metadata

Authors
Pantziarka, P., Sukhatme, V., Bouche, G., Melhuis, L., & Sukhatme, V. P.
Venue
ecancermedicalscience
Published
2016-01-11
Volume
10
Pages
610-610
ISSN
1754-6605 (ISSN-L)
OpenAlex
W2401840438
Cited by
118
References
8
FWCI
7.04
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent. https://app.cochat.ai/papers/10.3332/ecancer.2016.610
The paper
Pantziarka, P., Sukhatme, V., Bouche, G., Melhuis, L., & Sukhatme, V. P. (2016). Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent. ecancermedicalscience. https://doi.org/10.3332/ecancer.2016.610

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.